Sernova’s Search for a Cure

There is a staggering amount of research going into a diabetes cure with lots of progress toward lasting insulin-independence. We’ve discussed the ongoing research for a cure at length, but today we’re doing an even deeper dive with Sernova. Its unique approach involves implanting insulin-producing cells into a bioengineered cell pouch, offering hope for a future where type 1 diabetes (T1D) could become a thing of the past. But as with any breakthrough, challenges remain—immunosuppressants, scalability, and long-term viability.

In my recent conversation with the CEO of Sernova (and fellow T1D), Jonathan Rigby, I got a firsthand look at the company’s mission, the technology behind the cell pouch, and the exciting road ahead. Here are some key takeaways from our discussion:

• The Cell Pouch Technology: Sernova’s implantable device, made of a surgical mesh, allows blood vessels to integrate and nourish insulin-producing cells. Once implanted under the skin, it mimics a bio-hybrid organ that produces insulin as needed.

• Early Success in Clinical Trials: In its initial trials, six patients achieved insulin independence, with one patient remaining insulin-free for over four years. 

• Challenges of Immunosuppression: Currently, patients need immunosuppressants to prevent the body from rejecting the implanted cells, which makes them more susceptible to infection and other diseases. However, research is underway to develop gene-edited cells that could eliminate this requirement altogether.

• The Shift to Stem Cell-Derived Islet Cells: Sernova has partnered with Evotec to create a reliable and scalable supply of insulin-producing cells. This approach eliminates dependence on cadaveric donor cells, ensuring consistency and quality.

• The Competitive Landscape: Other companies, like Sana Biotechnology and Vertex, are also working on cell-based therapies, some aiming to bypass immunosuppression altogether. Each breakthrough in the field is bringing us all closer to a cure.

Jonathan remains hopeful that one day, people will look back and say, “Remember diabetes?” as a thing of the past. Until then, researchers, investors, and those of us living with diabetes continue pushing forward, step by step, toward a future without T1D. Watch the episode or listen above to hear more about how Sernova is getting us one step closer to a cure for type 1 diabetes.

Want to help advance diabetes research and get paid for it? 

Head to the T1D Exchange Registry, where a quick 15-minute survey is all it takes to make an impact. By signing up, you’ll gain access to a personal portal with future survey and clinical trial opportunities—some of which offer compensation.

Sign up here to be part of the future of diabetes innovation. Available for US residents only.

Product link disclosure - In order to provide free content, we use affiliate links. This means if you make purchases through certain links, we may earn a small commission (at no extra cost to you).